论文部分内容阅读
目的:分析乳腺导管原位癌的前哨淋巴结临床及病理特征,探讨乳腺导管原位癌患者实施前哨淋巴结活检的指征。方法:回顾性分析2002年10月到2010年11月期间诊断为乳腺导管原位癌并行前哨淋巴结活检的46例患者的的前哨淋巴结状态及其与其他临床及病理特征的关系。结果:患者的年龄、肿瘤大小、检出SLN数、肿瘤分级、切缘状态、DCIS类型、是否伴随坏死均无显著统计学意义(P>0.05)。可能与乳腺导管原位癌患者前哨淋巴结阳性的几个因素为:年龄41岁-69岁、肿瘤大小1.1 cm-5.0cm、切缘状态未知、肿瘤坏死伴随或未知、肿瘤分级Ⅰ级以上或未知。结论:以下几个因素可能对预测DCIS患者可能出现SLN阳性提供帮助,临床在遇到出现这些因素的DCIS患者需慎重考虑其治疗策略,这些因素包括:年龄41岁-69岁、肿瘤大小1.1cm-5.0 cm、切缘状态未知、肿瘤坏死伴随或未知、肿瘤分级Ⅰ级以上或未知。
OBJECTIVE: To analyze the clinical and pathological features of sentinel lymph node in situ ductal carcinoma of breast and to evaluate the indications of sentinel lymph node biopsy in patients with ductal carcinoma in situ. Methods: The sentinel lymph node status and its relationship with other clinical and pathological features were retrospectively analyzed in 46 patients with concurrent diagnosis of ductal carcinoma in situ and with sentinel lymph node biopsy from October 2002 to November 2010. Results: There was no significant difference in age, tumor size, number of detected SLNs, grade of tumor, status of incision, type of DCIS, and whether accompanied with necrosis (P> 0.05). There are several factors that may be associated with sentinel lymph node metastasis in patients with ductal carcinoma in situ: age 41-69 years, tumor size 1.1-5.0 cm, unknown margins, tumor necrosis with or without tumor grade I or above, or unknown . CONCLUSIONS: Several factors may help predict possible positive SLNs in DCIS patients. Patients with DCIS who have clinically encountered these factors need to carefully consider their treatment strategies, including age 41-69 and tumor size 1.1cm -5.0 cm, unknown margin status, tumor necrosis with or without tumor grade Ⅰ or above or unknown.